摘要
目的:比较帕利哌酮(芮达)与齐拉西酮(卓乐定)治疗精神分裂症的疗效和安全性。方法:选择符合CCMD-3诊断的精神分裂症患者86例,随机分为两组,分别使用帕利哌酮与齐拉西酮口服治疗,观察8周。以阳性及阴性症状量表(PANSS)减分率评定疗效,以个人和社会功能量表(PSP)评定社会功能,用治疗中出现的症状量表(TESS)评定不良反应。结果:治疗结束时,帕利哌酮组与齐拉西酮组在有效率、PANSS评分和不良反应两组比较差异无统计学意义(P>0.05),两者PSP评分有统计学意义(P<0.001)。结论:帕利哌酮与齐拉西酮治疗精神分裂症疗效均好,不良反应轻。在改善个人和社会功能方面,帕利哌酮明显优于齐拉西酮。
Objective：To compare the efficacy and safety of Paliperidone and Ziprasidone I n the treatment of Schizophrenia.Methods：86 patients with schizophrenia by CCMD-3 were randomly into two groups treated with Paliperidone or Ziprasidone for 8 weeks..The ratio of the reduction of Positive and Negative Symptom Scale（PANSS） was used to assess efficacy,and Personal and Social Performance Scale（PSP） was used to assess social function,while the treatment emergent symptom scale（TESS） was used to assess side effects.Results： In the end of curing,the two groups showed no statistical difference in the efficacy rate,the scores of PANSS,and the adverse effect（P〉0.05）.There was statistical significance in the scores of PSP for the two groups（P〈0.001）.Conclusions： Both Paliperidone and Ziprasidone are effective and few adverse effect for patients with schizophrenia.The Paliperidone is more effective than the Ziprasidone in terms of improving Personal and Social Performance Scale.
出处
《中国民康医学》
2012年第1期21-22,25,共3页
Medical Journal of Chinese People’s Health
作者简介
通信作者：杨逢润E—mail：yydstrong@163．com。
